Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
NCT06489249
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Electronic Cigarette Use
- Endothelial Dysfunction
- Inflammation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 to 24 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Iowa
- Last updated on ClinicalTrials.gov
- December 15, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Iowa · 2
- Iowa Bioscience Innovation Facility · Iowa City, IA
- University of Iowa · Iowa City, IA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.